Skip to main content

Table 1 Patient characteristics at baseline by serum adjusted calcium levels

From: Relationship between serum calcium level at dialysis initiation and subsequent prognosis

Variables All
n = 1517
G1
n = 114
G2
n = 241
G3
n = 530
G4
n = 522
G5
n = 110
p trend
Age (years old) 67.5 + 13.1 60.4 + 14.0 63.8 + 13.4 69.2 + 12.5 68.8 + 12.7 68.2 + 11.9 <0.001
Female gendera 491 (32.4) 43 (37.7) 61 (25.3) 167 (31.5) 176 (33.7) 44 (40.0) 0.033
BMI (kg/m2) 23.5 + 4.4 23.5 + 4.2 24.7 + 4.9 23.5 + 4.4 23.1 + 4.1 23.1 + 4.4 <0.001
SBP (mmHg) 151 + 26 154 + 24 154 + 28 152 + 25 150 + 26 148 + 28 0.129
DBP (mmHg) 77 + 15 82 + 14 80 + 17 77 + 15 76 + 15 74 + 15 <0.001
Diabetes Mellitusa 774 (51.0) 39 (34.2) 125 (51.9) 275 (51.9) 275 (52.7) 60 (54.5) 0.007
Cancer-bearing 93 (6.1) 5 (4.4) 16 (6.6) 32 (6.0) 32 (6.1) 8 (7.3) 0.914
History of CVD 681 (44.9) 29 (25.4) 98 (40.6) 248 (46.8) 251 (48.1) 55 (50.0) <0.001
Barthel index scoreb 100 (90-100) 100 (100-100) 100 (100-100) 100 (90-100) 100 (80-100) 100 (50-100) <0.001
Use of ACEIs or ARBsa 913 (60.2) 64 (56.1) 146 (60.6) 323 (60.9) 315 (60.3) 65 (59.1) 0.896
Use of beta blockersa 525 (34.6) 32 (28.1) 89 (36.9) 197 (37.2) 182 (34.9) 25 (22.7) 0.025
Use of VDRAsa 412 (27.2) 30 (26.3) 58 (24.1) 142 (26.8) 143 (27.4) 39 (35.5) 0.290
Use of calcium carbonatea 531 (35.0) 45 (39.5) 91 (37.8) 194 (36.6) 165 (31.6) 36 (32.7) 0.254
Use of thiazidea 347 (22.9) 18 (15.8) 62 (25.7) 134 (25.3) 109 (20.9) 24 (21.8) 0.117
Use of ESAsa 1303 (85.9) 92 (80.7) 203 (84.2) 476 (89.8) 449 (86.0) 83 (75.5) <0.001
Hemoglobin (g/dL) 9.4 + 1.6 8.8 + 1.8 9.4 + 1.5 9.5 + 1.5 9.4 + 1.6 9.4 + 1.4 0.002
Serum albumin (g/dL) 3.20 + 0.60 3.44 + 0.45 3.25 + 0.58 3.29 + 0.54 3.10 + 0.62 2.89 + 0.67 <0.001
BUN (mg/dL) 91.8 + 30.4 105.3 + 34.3 96.9 + 31.7 90.7 + 27.5 88.1 + 29.5 89.1 + 36.0 <0.001
eGFR (ml/min/1.73 m2) 5.44 + 2.22 4.21 + 1.36 4.92 + 1.95 5.44 + 1.92 5.77 + 2.28 6.30 + 3.48 <0.001
Serum creatinine (mg/dL) 8.98 + 3.22 11.53 + 4.52 9.97 + 3.21 8.75 + 2.83 8.35 + 2.73 8.23 + 3.72 <0.001
Serum adjusted calcium (mg/dL) 8.62 + 1.06 6.37 + 0.52 7.50 + 0.29 8.51 + 0.28 9.34 + 0.27 10.45 + 0.59 <0.001
Serum phosphorus (mg/dL) 6.36 + 1.88 7.89 + 2.24 7.01 + 1.95 6.22 + 1.62 5.97 + 1.77 5.97 + 1.92 <0.001
Alkaline phosphatase (IU/L) 265 + 173 291 + 137 272 + 144 260 + 164 259 + 202 265 + 155 0.441
PTH (pg/mL)b 292 (186-432) 440 (329-625) 375 (274-518) 307 (208-429) 231 (147-360) 150 (71-230) <0.001
CRP (mg/dl)b 0.30 (0.10-1.34) 0.31 (0.09-1.36) 0.32 (0.10-1.24) 0.20 (0.09-0.99) 0.30 (0.10-1.53) 0.62 (0.18-5.41) <0.001
Duration of NCb 588 (160-1307) 576 (77-1226) 579 (195-1107) 636 (208-1295) 573 (132-1509) 465 (80-1161) 0.517
  1. Mean ± SD, avalue (%), bmedian (inter-quartile range)
  2. G1 with a serum adjusted calcium level <7.0 mg/dL, G2 with 7.0 to <8.0 mg/dL, G3 with 8.0 to <9.0 mg/dL, G4 with 9.0 to <10.0 mg/dL, and G5 with ≥10.0 mg/dL
  3. BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, CTR cardiothoracic rate, CVD cardiovascular disease, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin-1 receptor blocker, VDRA vitamin D receptor activator, ESA erythropoiesis stimulating agent, BUN blood urea nitrogen, eGFR estimated glomerular filtration rate, PTH parathyroid hormone, CRP C reactive protein, NC nephrologist care